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ABSTRACT
Background: Influenza virus is a major trigger of asthma exacerbation. Annual vaccination against influenza
should be considered for asthmatics. However, the inoculation rates remain low. One reason may be the lack of
evidence supporting the benefit of the vaccination for patients with asthma．
Methods:We studied 115 adults with asthma in 2002―2003 and 67 in 2001―2002 and evaluated the effect of
influenza vaccination on the prevention of asthma exacerbation during the winter season (December―March)．
Results: The rate of asthma exacerbation per person was significantly lower in asthmatics who received influ-
enza vaccination (0.14 ± 0.4) during the 2002―2003 season than in asthmatics who did not (0.35 ± 0.61) ( p =
0.037). During 2001―2002 season, the rate of asthma exacerbation in the vaccinated group (0.08 ± 0.41) ap-
peared to be lower than that in the non-vaccinated group (0.27 ± 0.59). However, the difference between the
two groups was not statistically significant ( p = 0.143), presumably due to the low number of patients receiving
vaccination. Severe adverse effects due to vaccination were not observed in the patients analyzed．
Conclusions: Influenza vaccination during the winter season appears to be effective in the prevention of
asthma exacerbation and should be recommended for patients with asthma．
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INTRODUCTION
Respiratory infection can exacerbate asthma . Viral
pathogens, such as human rhinovirus (HRV), coro-
navirus, influenza virus, parainfluenza virus, respira-
tory syncytial virus and adenovirus, are often respon-
sible . 1-3 HRV is an important pathogen leading to
asthma attacks. However, influenza epidemics in win-
ter are also a threat. Podosin et al. reported asthma
exacerbation induced by influenza virus, and since
then evidence of the effects of influenza on asthma
has been reported.4,5 Infection with influenza virus
renders asthmatics more susceptible to bronchocon-
striction, exacerbation of asthma, and prolonged de-
clines in lung function . 6 Influenza-induced severe
asthma attacks and hospitalization are associated
with needless deaths, particularly in the elderly.7-9
Among of the viruses that cause airway infection,
influenza is the one for which vaccinations are estab-
lished and available. The efficacy of influenza vaccina-
tion in the prevention of infection has been re-
ported.10-12 Recent reports support the safety of influ-
enza vaccine for asthmatics.13,14 However, the num-
bers of asthmatics that received annual influenza vac-
cine are reportedly very few.15 One reason may be
that physicians and patients are not aware of the
benefit of the influenza vaccine for asthma. Several
reviews have indicated that the benefit of influenza
vaccination in patients with asthma is modest or un-
clear.16,17 There are few studies on the prevention of
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Table 1 Characteristics of Subjects
2002/2003 season
Not-vaccinated SubjectsVaccinated Subject
 58 （ 50.4%） 57 （ 49.6%）Number of subjects（%）
 51.1 （15―84） 62.3 （24―89）Age
27/3116/41Male/Female
Number of Asthma type
 20 21Alergic
 38 36Non-alergic
Severity
 0 （ 0%） 1 （ 1.8%）Intermitent
 8 （ 13.8%） 5 （ 8.8%）mild persistent
 24 （ 41.4%） 25 （ 43.9%）moderate persistent
 26 （ 44.8%）　 26 （ 45.6%）severe persistent
2001/2002 season
Not-vaccinated SubjectsVaccinated Subject
 43 （ 64.2%） 24 （ 35.8%）Number of subjects（%）
 52.0 （15―84） 64.3 （ 31―89）Age
16/278/16Male/Female
Number of Asthma type
 15 10Alergic
 28 14Non-alergic
Severity
 0 （ 0%） 1 （ 4.2%）Intermitent
 5 （ 11.6%） 3 （ 12.5%）mild persistent
 13 （ 30.2%） 8 （ 33.3%）moderate persistent
 25 （ 58.1%） 12 （ 50.0%）severe persistent
asthma exacerbation by influenza vaccination are
few.18 We studied the effect of influenza vaccination
on asthma and investigated whether influenza vacci-
nation could prevent asthma exacerbation during the
winter season in Japan.
METHODS
We studied 115 adult patients with asthma (age 15―89
years) in 2002―2003 and 67 (age 15―89) in 2001―2002.
Asthma was defined as recurrent episodes of airway
obstruction that resolved on treatment . Diagnosis
was made by a clinical specialist with follow-up every
14―28 days at the Respiratory Division of Showa Uni-
versity Hospital or Ohta-Fukushima General Hospital.
Most of the patients self-checked their peak expira-
tory flow (PEF) and self-recorded their symptoms.
Patients who also had chronic obstructive pulmonary
disease (COPD) were excluded . Among these pa-
tients, we studied all who received influenza vaccina-
tion from November to December in 2001 or 2002
and those with similar characteristics who did not re-
ceive vaccination were chosen randomly . We ex-
cluded patients who might have received vaccination
at other hospitals. Then we retrospectively analyzed
the data．
We evaluated “influenza-like illness” symptoms as-
sociated with influenza infection according to pa-
tients’ symptoms using a scoring method.3,5,11 Each
symptom, such as sore throat or rhinorrhea, fever,
general fatigue, cough, and sudden onset , was as-
signed one point, and a total of three or more points
were defined as influenza-like illness. Some patients
who were evaluated as influenza-like illness were
positively diagnosed with influenza using an influenza
antigen detection kit. However we could not check all
patients using this kit, therefore the symptom score
was used. Asthma attacks accompanied by wheezing
or a decrease of more than 20% in PEF was defined as
exacerbation. Patients with constant wheezing were
excluded from this study. Exacerbations of asthma
were evaluated by specialists according to the guide-
lines of the Japanese Society of Allergology．
To investigate the effect of influenza vaccination on
the prevention of asthma exacerbation, we followed
patients from December 1 to March 31 because these
four months comprise the epidemic season of influ-
enza in Japan. The number of exacerbation of asthma
accompanied by influenza-like illness were calculated
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Table 2 Efect of Influenza vaccination on the asthma exacerbations
2002/2003 season
p ValueNot-vaccinated SubjectVaccinated Subject
5857Person
208No. of exacerbations
0.0370.35±0.610.14±0.4Mean±S.D.
2001/2002 season
p ValueNot-vaccinated SubjectVaccinated Subject
4324Person
122No. of exacerbations
0.1430.27±0.590.08±0.41Mean±S.D. 
Table 3 Efect of Influenza vaccination on the exacerbations of asthma who were controled within Green-Zone before winter 
season in 2002/2003.
p ValueNot-vaccinated SubjectsVaccinated Subjects
Patients controled
3132within Green-zone
102No. of exacerbations
0.0490.32±0.650.06±0.25Mean±S.D.
per person. Data analysis was performed with the use
of Stat-View IV (Abacus Concepts, Inc., Berkeley, CA,
USA). The data are expressed as mean ± standard de-
viation (SD). Statistical differences were determined
by analysis of variance with Fisher protected least
significant difference．
RESULTS
Characteristics of the study population are shown in
Table 1. The severity of asthma was assessed by the
use of daily medications according to the guidelines
of the Global Initiative for Asthma (GINA). The char-
acteristics were similar between the group that re-
ceived influenza vaccination and the group that did
not．
In the 2002―2003 season, the number of asthma ex-
acerbations per person accompanied by influenza-like
illness was significantly lower in the group with vacci-
nation (0.14 ± 0.4, mean ± SD) than in the group with-
out vaccination (0.35 ± 0.61) (p = 0.037). In the 2001―
2002 season, the number of asthma exacerbations per
person accompanied by influenza-like illness tended
to be lower in the vaccination group, but the differ-
ence was not statistically significant (p = 0.143)(Table
2)．
To minimize the effects of factors other than respi-
ratory infection triggering exacerbations, we also as-
signed some patients to the green zone group which
included patients whose asthma was stably controlled
(PEF was kept within 80% of the highest value) for 3
months before the winter season. In the green zone
group, the number of asthma exacerbations per per-
son was lower in those patients receiving vaccination
(0.06 ± 0.25) than in those not receiving vaccination
(0.32 ± 0.65) (p = 0.049) during the 2002―2003 season
( Table 3 )．
DISCUSSION
In this study, we showed that influenza vaccination
could reduce the number of asthma exacerbations
caused by influenza-like illness during the winter sea-
son．
In Japan, vaccination rates have decreased since
the law mandating vaccination of school children in
1994. Needless deaths caused by influenza infection
have increased since then,19 and the Japanese gov-
ernment has attempted to increase the rate of influ-
enza vaccination again . The government amended
the law and provided influenza vaccination financial
support for the elderly in 2001. Vaccination rates have
increased since 2001, but they remain low compared
to those in Western countries. Therefore, the number
of patients studied in the 2001―2002 season was less
than that in 2002―2003. The lack of statistically signifi-
cant effects of vaccination in the 2001―2002 season
may be due to insufficient numbers of patients. Ac-
cording to National Institute of Infectious Disease ,
the Number of Influenza infection in 2001―2002 was
relatively lower than that in 2002―2003. The differ-
ence of prevalence between the seasons may also in-
fluence the results．
The influenza season in Japan is from December
through March. We did not detect statistically signifi-
cant effects of the influenza vaccine when asthma ex-
acerbation triggered by factors other than influenza-
like illness were included (data not shown). However,
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influenza vaccination clearly prevented asthma exac-
erbation that occurred when symptoms of influenza-
like illness were present. These findings indicate that
influenza infection may be just one factor that trig-
gers asthma attacks, and other factors, such as cold
air, changes in weather, stress, pollen, or antigens,
may also be important. The effect of influenza vacci-
nation in the prevention of total exacerbations of
asthma appears to be minor. However, influenza in-
fection can be prevented or its virulence may be
weakened by immunization. Therefore, influenza in-
fection should be given serious consideration, and its
prevention by vaccination should be recommended
for patients with asthma．
In our study, even patients in green zone group
had asthma attacks in the presence of influenza-like
illness or respiratory infection. Influenza vaccination
was effective in preventing asthma exacerbation in
these patients . Recent therapies for asthma have
been improved, and medications such as inhaled cor-
ticosteroids are standard treatments . However , our
data indicate that prevention of viral infection or mini-
mization of virulence could improve the control of
asthma．
Although GINA recommends influenza vaccination
for asthmatics, the number of asthmatics receiving
vaccination is low. One reason may be that physicians
and patients doubt the safety of the influenza vaccine.
Previous reports indicated that influenza vaccination
could cause a decrease in PEF.17,18 However, recent
well designed and placebo-controlled trials showed
the safety of the inactivated split-virus influenza vac-
cine, which is commonly used in Japan. The Ameri-
can Lung Association Asthma Clinical Research Cen-
ters studied 2032 patients with asthma and reported
that the frequency of exacerbation of asthma was
similar between groups injected with the influenza
vaccine or with placebo.14 A previous report, which
studied a smaller number of asthmatics , indicated
that pulmonary function abnormalities might occur
within 3 days of influenza vaccination. However, the
authors suggested that this effect was minor and out-
weighed by the advantages of vaccination.13 We also
did not detect prominent systemic side effects or
asthma exacerbation in patients who received influ-
enza vaccination (data not shown)．
Further study is necessary to determine the
mechanisms by which influenza vaccination prevents
asthma exacerbation . Several mechanisms can be
hypothesized. First , influenza vaccination may pre-
vent influenza infection, resulting in reduced triggers
of asthma exacerbation. In this study, we could not
compare the rates of prevention of influenza infection
between asthmatics who received and those who did
not receive vaccination . However , it has been re-
ported that the efficacy of the influenza vaccine in the
prevention of infection is approximately 60%―80%.10-12
Second, influenza vaccination may interfere with cy-
tokine production induced by influenza infection. In-
fluenza virus is known to induce several kinds of cy-
tokines that are known to cause airway inflammation,
including asthma exacerbation.20-22 Several investiga-
tors have reported that the influenza vaccination re-
duces the production of cytokines, such as TNFα, IL-
1, IL-6, and IL-8, which may be induced by influenza
infection. In those in whom influenza vaccine does
not prevent infection, it may decrease cytokine pro-
duction and minimize airway symptoms , including
asthma attacks.23,24
Taken together, these data indicate that vaccina-
tion against influenza is beneficial for asthmatics .
Even though it only protects against influenza-
induced symptoms, vaccination may be clinically im-
portant and should be recommended. More efforts to
increase the vaccination rates of asthmatics will likely
improve the control of asthma overall．
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